Drug Manufacturers - Specialty & Generic•Small Cap
Clear visual breakdown: for every ₹100 earned, see how much flows to salaries, operating costs, government taxes, EPS profit, and your share.
High profit margin business
Workforce salaries, engineers & talent
Annual profit generated per stock unit
Direct cash dividends & buybacks
Select or type any investment amount to see how much commercial activity and earnings your money commands in ANLON HEALTHCARE LIMITED.
Anlon Healthcare Limited manufactures and sells active pharmaceutical ingredients in India and internationally. The company also offers bulk drugs; advanced pharmaceutical intermediates; nutraceutical API products; and drug intermediates. It also manufactures loxoprofen sodium dihydrate, ketoprofen, and dexketoprofen trometamol products for pain management and anti-inflammatory therapies. Anlon Healthcare Limited was incorporated in 2013 and is based in Rajkot, India.
Comparing ANLON HEALTHCARE LIMITED with leading competitors in Healthcare & Pharma (Indian Market)
| # | Company Name | CMP | 1D % | P/E | Market Cap | Div Yield | 1Y Return |
|---|---|---|---|---|---|---|---|
| 1 | ANTHEM BIOSCIENCES LTD(ANTHEM) | ₹915.55 | +0.22% | 84.8 | ₹51,594 Cr | 0.22% | +31.15% |
| 2 | DR AGARWALS HEALTH CARE L(AGARWALEYE) | ₹516.35 | +0.91% | 94.9 | ₹16,371 Cr | 0.00% | +1.58% |
| 3 | ADVANCED ENZYME TECH LTD(ADVENZYMES) | ₹280.30 | -1.41% | 18.1 | ₹3,023 Cr | 0.48% | -8.41% |
| 4 | ANLON HEALTHCARE LIMITEDCurrent | ₹27.00 | -3.54% | 49.1 | ₹1,435 Cr | 0.00% | +101.14% |
| 5 | 3B BLACKBIO DX LTD.(3BBLACKBIO) | ₹1,284.20 | -1.90% | 19.1 | ₹1,102 Cr | 0.39% | +13.99% |
| 6 | ANUH PHARMA LIMITED(ANUHPHR) | ₹81.55 | -0.74% | 18.4 | ₹817 Cr | 1.84% | -4.38% |
| 7 | AAREY DRUGS & PHARM LTD(AAREYDRUGS) | ₹107.72 | -1.52% | 72.3 | ₹343 Cr | 0.00% | +12.46% |
Quotes are delayed by at least 15 minutes. Financial metrics and disclosures are cross-referenced with periodic statutory disclosures from the National Stock Exchange of India (NSE) and BSE India. This content is provided strictly for educational and portfolio analytics purposes, and does not constitute investment advice or Buy/Sell recommendations.